Signos gets $20 million to expand CGM use beyond diabetes and toward weight loss

Signos raised $20 million to expand its glucose monitoring platform for weight loss, which combines Dexcom’s over-the-counter CGM with an app that translates glucose data into personalized diet and lifestyle recommendations.

The post Signs Gets $20 Million to Expand CGM Use Beyond Diabetes and Achieve Weight Loss appeared first on MedCity News.